According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “
A number of other brokerages also recently issued reports on VTL. BTIG Research restated a hold rating on shares of Vital Therapies in a research report on Friday. Canaccord Genuity set a $10.00 price objective on Vital Therapies and gave the company a buy rating in a research report on Monday, January 2nd.
Vital Therapies (NASDAQ:VTL) opened at 4.35 on Friday. Vital Therapies has a 1-year low of $3.85 and a 1-year high of $9.73. The stock has a 50 day moving average price of $4.65 and a 200-day moving average price of $5.31. The stock’s market cap is $139.42 million.
Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Tuesday, March 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by $0.01. During the same quarter last year, the firm posted ($0.34) earnings per share. On average, equities analysts expect that Vital Therapies will post ($1.51) EPS for the current year.
“Vital Therapies Inc (VTL) Downgraded to Sell at Zacks Investment Research” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another website, it was illegally stolen and republished in violation of US and international trademark & copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/03/11/vital-therapies-inc-vtl-downgraded-to-sell-at-zacks-investment-research.html.
Large investors have recently modified their holdings of the stock. Victory Capital Management Inc. acquired a new position in Vital Therapies during the third quarter worth approximately $14,214,000. State Street Corp boosted its position in Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in Vital Therapies during the third quarter worth approximately $321,000. Institutional investors and hedge funds own 26.68% of the company’s stock.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc and related companies with MarketBeat.com's FREE daily email newsletter.